Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyorin Gains Rights to Merck’s OAB Med in Asia
Kyorin Pharmaceutical has acquired exclusive rights to develop and commercialize US Merck’s overactive bladder (OAB) treatment KRP-114V (vibegron) in Asia in a deal expanding their original agreement that only covered the Japanese market. Under the latest deal, Kyorin newly obtained…
To read the full story
Related Article
- Kyorin Out-Licenses Vibegron to Sumitomo in 5 Asian Markets
March 7, 2023
- Eisai Snags Rights to Vibegron in 4 ASEAN States
April 1, 2021
- Kyorin, Kissei to Jointly Develop, Market OAB Treatment
March 31, 2016
- Kyorin Licenses OAB Treatment Vibegron from Merck
July 24, 2014
BUSINESS
- Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
- Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
- UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
March 3, 2026
- Itochu Snaps Up CoreMed to Bolster Japan Entry Support
March 3, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…